Li D, Tan R, Hernandez S, Reilly N, Bussberg C, Mansfield C. Patient preferences for unresectable hepatocellular carcinoma treatments: a discrete-choice experiment. Cancers. 2023 Feb 25;15(5):1470. doi: 10.3390/cancers15051470
Menon AP, Moreno B, Meraviglia-Crivelli D, Nonatelli F, Villanueva H, Barainka M, Zheleva A, van Santen HM, Pastor F. Modulating T cell responses by targeting CD3. Cancers. 2023 Feb 13;15(4):1189. doi: 10.3390/cancers15041189
Drummand M, Members of the ISPOR HTA Council Working Group on HTA in Pluralistic Healthcare Systems, Ronquest N. A case of multitasking: conducting and using HTA and HEOR in pluralistic healthcare systems. Value & outcomes spotlight. 2022 Jul;8(4):7-9.
Wolowacz SE. Task force recommendations on the collection of health-state utility data in clinical studies: an interview with Sorrel E. Wolowacz, PhD, Co-Chair, on good practices for Outcomes Research Task Force. Value & outcomes spotlight. 2016 Sep;2(5):22-3.
Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring health-state utility values in clinical trials: can we do better? Ispor Connections. 2014 Sep;20(5):4-8.
Stull DE, Houghton KF, Petrillo J. Innovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trials. Ispor Connections. 2013;19(1):5-8.
Masters E, Zlateva G, Harris NI. Real-world data for use in the real world: the pain paradigm. Ispor Connections. 2013;19(2):9-11.
Wolowacz SE, Khan SB. The New National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: experience from the first completed appraisals. Ispor Connections. 2007;13(2):12-5.
Mansfield CA. A consistent method for calibrating contingent value survey data. South Econ J. 1998;64(3):665-81.